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Nano- and microparticles are used in the pharmaceutical industry for sustained
release drug delivery systems. For example, polymeric particles are currently used as
an FDA-approved drug delivery system for leuprolide acetate to treat prostate
cancer1. Our drug of interest is CPDI-02 (formerly known as EP67)—a C5a-derived
decapeptide agonist of the C5a Receptor (CD88) that activates mononuclear
phagocytes to produce an immune response while potentially minimizing neutrophilmediated toxicity2. Currently in the Vetro Lab, CPDI-02 is being tested on pigs and
mice to treat methicillin-resistant Staphylococcus aureus (MRSA) infections and as
the adjuvant for a vaccine for cytomegalovirus (CMV). This investigation explored
formulation parameters that impact particle size and loading of CPDI-02 in a
traditional oil-in-water (O/W) emulsion. We also explored adapting the formulation
using microfluidic chips to generate nano- and microparticles and improve run-to-run
consistency in particle size.
Tyr-Ser-Phe-Lys-Asp-Met-Pro-[Me-Leu]-[D-Ala]-Arg

Table 1. Increasing viscosity of the DP improves encapsulation efficiency of CPDI-02

METHODS

ABSTRACT

• Form CP by making a filtered 2% (m/v) solution of PVA
• Form DP by dissolving PLGA in 1 mL dichloromethane (DCM), acetonitrile, or ethyl
acetate
• Dissolve 5 mg CPDI-02 in 300 µL methanol and combine with DP to form a cosolvent oil
phase
• For traditional emulsion: add 1 mL 2% PVA to DP and vortex (1,000 RPM) to form an
O/W emulsion
• For microfluidic emulsion: pump DP and CP through chip using syringe pumps
• Transfer emulsion to a beaker with CP and evaporate organic solvent with stirring (300
RPM) until particles harden overnight
• Centrifuge and wash with D/I to remove PVA and recover harden particles (3X)
• Lyophilize for 48 hours
• Determine particle size using NanoSight (nanoparticles) or Nexcelcom (microparticles)
• Assay loading (if applicable) using microBCA. Known mass of particles was dissolved in
300 µL DMSO to disrupt polymer matrix, then stirred overnight in 0.05 M NaOH and 0.5%
SDS to digest polymer

Figure 1. Amino acid sequence of CDPI-02

Condition

Encapsulation (%)

100 mg PLGA

12.0

350 mg PLGA

83.2

350 mg PLGA (0.1 M NaCl)

81.5

  0.05% for n = 3 internal replicates

EXPERIMENTS

BACKGROUND

• Varied viscosity comparing impact on size (350 mg PLGA /mL solvent and 100 mg
PLGA/ mL solvent)
Traditional Approaches to the Formation of Micro- and Nanoparticles
• Varied energy by increasing vortex time (30 sec versus 60 sec) to determine impact on
• Typically, emulsions are used to form polymeric micro- and nanoparticles
size
• The emulsion consists of two phases:
• Varied viscosity comparing impact on encapsulation (350 mg PLGA /mL solvent and 100
▪ The dispersed phase (DP) is usually an organic solvent containing both the
mg PLGA/ mL solvent)
desired drug and a polymer—poly(lactic-co-glycolic acid) (PLGA)
• Attempt to replicate above using microfluidic chips
▪ The continuous phase (CP) is a solution of water and poly(vinyl alcohol) (PVA)—a
surfactant that prevents aggregation and coalescence of the dispersed phase
RESULTS
• The amount of energy applied to create the emulsion determines the size of the
particles obtained
15
• Sources of energy include shaking, vortexing, stirring, homogenization, and
100 mg / mL - 60 sec
sonication

Microfluidic chip-based emulsion
• Herringbone: turbulence in the mixing region impacts nanoparticle size
• Droplet-generator: DP and CP flow rates causes sheer that impacts microdroplet
size
• Advantage: Reproducibility and conformity in particle size
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Figure 6. microBCA calibration curve used in determination of CPDI-02
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Figure 7. NanoSight sizing of nanoparticles produced using a herringbone microfluidic
chip (40 mg PLGA / mL acetonitrile with DP rate of 1 mL/min and CP rate of 9 mL/min)
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Figure 3. Fluidic 440 Droplet-generator
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Limitations of the Traditional Approach
• Reproducibility and conformity in size
• Scalability

Percent

7.1 μm

Figure 2. Fluidic 187 Herringbone
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CONCLUSIONS

Figure 4. Traditional emulsion. Increasing viscosity (350 mg PLGA / mL solvent compared
to 100 mg PLGA / mL solvent) produced larger microparticles. Higher energy (60 sec Formulation parameters can significantly impact particle size and loading
vortex) produced smaller microparticles compared to 30 sec vortex with 100 mg PLGA / mL
Microfluidic droplet-generator chip-based emulsions
solvent emulsions
• Experienced problems with assembly, back-pressure, fluid flow, and precipitation
• Attempting to use new chip design for future experiments
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1. Determine if changes in viscosity (polymer concentration) affects particle size
2. Determine if the amount of energy applied affects particle size
3. Determine if changes in viscosity affects drug encapsulation
4. Evaluate parameters that impact particle size obtained using microfluidic chips

Figure 5. Image of microparticles (100 mg PLGA/ mL DCM) using Nexcelcom cell counter
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